EKF Diagnostics Investor Announcements
EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.
Studies confirm utility of PointMan for molecular analysis of CTCs and circulating DNA in liquid biopsies
EKF Diagnostics announces the UK launch of the Altair™ 240 clinical chemistry analyser at the Institute of Biomedical Science Congress 2015 in Birmingham, UK, 28-30 September.
EKF announces that two research posters supporting its PointMan™ molecular diagnostic technology have been delivered at key conferences.
Two research posters supporting PointMan™ molecular diagnostic technology have been delivered at key conferences.
Extension to deadline under Rule 2.6(c) of the City Code on Takeovers and Mergers.
EKF announces that it has recently won two new tenders for its Hemo Control point-of-care hemoglobin analyser.
EKF announces that it has recently won two new tenders for its Hemo Control point-of-care hemoglobin analyser.
Public Opening Position Disclosure by a Party to an Offer. Rules 8.1 and 8.2 of the Takeover Code.
Non-binding proposal for Point of Care division withdrawn.
Newsletter
Keep up to date with all our activities, events, exhibitions, promotions, investor news & more.